The apparent resurgence of interest after 2015 would have been consequent to the promising results seen for VMAT-2 inhibitors as a treatment method for TD and other hyperkinetic disorders (76, 81, 82) substantiated by the Food and Drug Authority (FDA) approval of two VMAT-2 inhibitors – valbenazine and deutetrabenazine- in 2017 for the treatment of TD. This evidence concerns the gene SLC18A2 and Hyperactivity.